DEA Telemedicine Prescribing Rules Run Through 2026
DEA and HHS extended telemedicine controlled-substance prescribing flexibilities through December 31, 2026. Here's what the fourth extension means and what to watch.
Practitioners can keep prescribing controlled substances by telemedicine — without a prior in-person visit — through December 31, 2026. That's the effect of the temporary rule DEA and HHS issued in the final days of December 2025 — the fourth extension of the prescribing flexibilities that began during the public health emergency.
The rule keeps the framework simple on its face: DEA-registered practitioners may prescribe Schedule II–V medications via telemedicine, regardless of when the practitioner-patient relationship was formed, provided the encounter and prescription meet the rule's conditions. State law still applies on top — and that's where much of the real complexity lives, since states layer their own prescription monitoring checks, e-prescribing mandates, and schedule-specific limits over the federal floor. Our state law guide tracks those differences.
Why this extension looks like the last one — and why that's the story
This is the fourth time DEA has extended the flexibilities rather than landing a permanent rule. The agency proposed a special registration framework in early 2025 — a pathway that would let qualifying practitioners prescribe via telemedicine under a dedicated registration — but it has not been finalized. Every extension buys another year of access for patients, and another year of uncertainty for anyone building a prescribing-dependent program.
The stakes are concentrated in a few areas of medicine. Telepsychiatry practices prescribing stimulants for ADHD or benzodiazepines, and opioid use disorder treatment built on buprenorphine started via telehealth, depend on this framework more than almost anyone else. If your program's economics assume telemedicine prescribing continues past 2026, that assumption deserves a contingency plan — most practically, a referral relationship or hybrid model that can absorb an in-person evaluation requirement if one returns. Our telepsychiatry guide covers how programs handle the controlled-substance question in practice.
What to watch between now and January 2027
Three things will tell you where this lands: whether DEA finalizes the special registration rule, whether Congress steps in legislatively, and whether a fifth temporary extension arrives late in the year — the last four have all been issued in the final weeks of December. We'll cover each development as it happens. Until then, treat December 31, 2026 as a real date: verify current requirements with DEA and your state board before writing prescribing policy around any of it.
Frequently asked questions
- Can controlled substances still be prescribed by telemedicine in 2026?
- Yes. Under the temporary rule DEA and HHS issued in late December 2025, DEA-registered practitioners can prescribe Schedule II–V controlled substances via telemedicine without a prior in-person evaluation through December 31, 2026, subject to the rule's requirements and state law.
- What happens to telemedicine prescribing after December 31, 2026?
- That is the open question. DEA has proposed a special registration framework but has not finalized it. Absent a new rule or another extension, the default federal requirement of a prior in-person evaluation under the Ryan Haight Act would return. Verify current status with DEA before relying on any pathway.
- Does the federal flexibility override state prescribing laws?
- No. State law applies on top of the federal framework. Several states impose their own limits on prescribing controlled substances via telemedicine, so a prescription that is federally permissible can still be barred by state rules.